Sawicki Krzysztof, Matysiak-Kucharek Magdalena, Gorczyca-Siudak Daria, Kruszewski Marcin, Kurzepa Jacek, Kapka-Skrzypczak Lucyna, Dziemidok Piotr
Department of Molecular Biology and Translational Research, Institute of Rural Health, 20-090 Lublin, Poland.
Department of Diabetes, Institute of Rural Health, 20-090 Lublin, Poland.
Int J Mol Sci. 2024 Dec 31;26(1):290. doi: 10.3390/ijms26010290.
Telomere shortening has been linked to type 2 diabetes (T2D) and its complications. This study aims to determine whether leukocyte telomere length (LTL) could be a useful marker in predicting the onset of complications in patients suffering from T2D. Enrolled study subjects were 147 T2D patients. LTL was measured using a quantitative PCR method. Key subject's demographics and other clinical characteristics were also included. T2D patients with the shortest LTL had higher TC and non-HDL levels, compared to subjects with the longest LTL ( = 0.013). Also, T2D patients suffering from diabetic nephropathy showed significant differences in LDL levels ( = 0.023). While in the group of T2D patients with diabetic retinopathy, significant differences were observed for parameters, such as duration of diabetes ( = 0.043), HbA1c ( = 0.041), TC ( = 0.003), LDL ( = 0.015), Non-HDL ( = 0.004) and TG ( = 0.045). Logistic regression analysis confirmed a significant risk of association of TC and Non-HDL levels with LTL in the 3rd tertile LTL for the crude model adjusted for sex and age, with respective odds ratios of 0.71 (95% CI 0.56-0.91) and 0.73 (95% CI 0.58-0.91). No significant associations were found between LTL in T2D patients and the prevalence of common T2D complications. Nevertheless, a significant association was demonstrated between LTL and some markers of dyslipidemia, including in T2D patients with either diabetic nephropathy or retinopathy. Therefore, analysis of LTL in T2D patients' leukocytes demonstrates a promising potential as a marker in predicting the onset of complications in T2D. This could also help in establishing an effective treatment strategy or even prevent and delay the onset of these severe complications.
端粒缩短与2型糖尿病（T2D）及其并发症相关。本研究旨在确定白细胞端粒长度（LTL）是否可作为预测T2D患者并发症发生的有用标志物。纳入的研究对象为147例T2D患者。采用定量PCR方法测量LTL。还纳入了关键研究对象的人口统计学数据和其他临床特征。与LTL最长的受试者相比，LTL最短的T2D患者总胆固醇（TC）和非高密度脂蛋白（non-HDL）水平更高（P = 0.013）。此外，患有糖尿病肾病的T2D患者低密度脂蛋白（LDL）水平存在显著差异（P = 0.023）。而在患有糖尿病视网膜病变的T2D患者组中，在糖尿病病程（P = 0.043）、糖化血红蛋白（HbA1c，P = 0.041）、TC（P = 0.003）、LDL（P = 0.015）、non-HDL（P = 0.004）和甘油三酯（TG，P = 0.045）等参数方面观察到显著差异。逻辑回归分析证实，在针对性别和年龄进行调整的粗模型中，处于LTL第三分位时，TC和non-HDL水平与LTL存在显著关联风险，优势比分别为0.71（95%置信区间0.56 - 0.91）和0.73（95%置信区间0.58 - 0.91）。未发现T2D患者的LTL与常见T2D并发症的患病率之间存在显著关联。然而，在LTL与某些血脂异常标志物之间显示出显著关联，包括在患有糖尿病肾病或视网膜病变的T2D患者中。因此，分析T2D患者白细胞中的LTL显示出作为预测T2D并发症发生的标志物的潜在前景。这也有助于制定有效的治疗策略，甚至预防和延缓这些严重并发症的发生。
